tradingkey.logo

Briacell, Briapro Enter Into Asset Purchase Agreement For Exclusive Soluble CD80 License

ReutersFeb 18, 2026 11:18 PM

- Briacell Therapeutics Corp BCT.TO:

  • BRIACELL AND BRIAPRO ENTER INTO ASSET PURCHASE AGREEMENT FOR EXCLUSIVE SOLUBLE CD80 LICENSE

  • BRIACELL THERAPEUTICS CORP - BRIAPRO GAINS WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE SCD80

  • BRIACELL THERAPEUTICS CORP - BRIAPRO TO PAY 2% ROYALTIES TO UMBC UPON COMMERCIALIZATION

  • BRIACELL THERAPEUTICS CORP - TO PROVIDE BRIAPRO UP TO $3 MILLION FOR RESEARCH AND DEVELOPMENT

  • BRIACELL THERAPEUTICS CORP: AS PART OF TRANSACTION, BRIACELL WILL MAKE AVAILABLE TO BRIAPRO UP TO $3 MILLION TO FUND RESEARCH AND DEVELOPMENT EFFORT

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI